Colgate-Palmolive Company (CL) — Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is cautiously constructive — consensus has drifted modestly lower since Q1 earnings, setting a manageable bar — but the single biggest swing factor is whether the North America category deceleration observed in early May has deepened or stabilized, as that dynamic is not yet fully reflected in estimates.

Heading into Q2 2026, Colgate faces a nuanced setup: the bar is not demanding — consensus organic sales growth of ~2.4% and operating EPS of ~$0.95 sit modestly below Q1's 2.9% organic print and $0.97 EPS — but the risk is that North America categories, which management flagged as "markedly slowing" in the first weeks of May at the Deutsche Bank conference, have deteriorated further into the quarter. Gross margin guidance was already revised to down for FY2026 (from previously expected up) at Q1 earnings, absorbing ~$300M of incremental raw material and logistics cost, so the gross profit line is a known headwind; the question is whether tariff normalization and productivity offsets are tracking as planned. Estimate revisions have been mildly negative since the Q1 print — FY2026 EPS consensus edged up slightly to $3.80 from $3.79, while revenue estimates drifted ~$5M lower — suggesting the Street has largely digested the gross margin reset without panic. The stock has outperformed both XLP (+3.5pp) and the S&P 500 (+2.1pp) since Q1 earnings, trading up ~5% to ~$91.60, implying the market has partially priced in execution stability; at ~24x forward P/E, the multiple leaves limited room for a negative surprise. The key wildcard is the trajectory of Hill's Pet Nutrition: private label headwinds were expected to taper to a ~20–30bp drag in Q2 and largely resolve by H2, and any upside there — combined with continued Latin America strength — could offset North America softness and drive a beat.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar on both organic sales growth (~2.4% vs. 2.9% in Q1) and operating EPS (~$0.95 vs. $0.97 in Q1); the bigger swing factor is gross margin trajectory — any sign of tariff/cost stabilization ahead of guidance could be the positive catalyst, while further North America category softness is the primary downside risk.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. Q1 2026 operating profit reflects SGPP charges; Q2 2025 operating profit was $1.080B. Note: Q2 2026 operating profit consensus of $1.095B implies YoY improvement as SGPP charges normalize.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Organic Sales Growth & Operating EPS)

Pattern: CL has beaten operating EPS consensus in all 8 of the last 8 quarters, with an average surprise of +3.1%; organic sales growth beats are less consistent (5 of 8), with misses concentrated in periods of category deceleration (Q1 2025, Q4 2024, Q3 2025). The EPS beat pattern is durable given CL's P&L flexibility, but organic growth is the more volatile and market-moving metric. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: The most significant post-Q4 2025 guidance change was the gross margin revision to down from up at Q1 2026 earnings (May 1), driven by ~$300M of incremental raw material and logistics costs; FY2026 EPS guidance range was maintained despite this, signaling P&L flexibility. At the June 3 Deutsche Bank conference, management kept EPS guidance range intact but flagged that the high end of the range had come down, and introduced a new demand risk: North America categories markedly slowing in early May.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since Q1 earnings — FY2026 EPS consensus edged up ~$0.008 while revenue drifted ~$5M lower — suggesting the Street has absorbed the gross margin reset without material revision pressure; the gap between current consensus and the original gross margin guidance is the key divergence, representing a known headwind rather than a new risk.

Estimates have been remarkably stable in the ~85 days since Q1 earnings, with organic sales growth and EPS consensus essentially flat. The gross profit line is the key divergence from original guidance — the revised "down YoY" gross margin guidance is now embedded in consensus, so any tariff normalization or productivity upside would be a positive catalyst. Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: CL has outperformed both XLP (+3.5pp) and the S&P 500 (+2.1pp) since Q1 earnings, with the stock up ~7.3% from $85.36 to $91.60 — performance has been revision-driven and defensive-rotation-driven rather than multiple expansion, as the stock re-rated modestly higher on stable estimates and the market's flight to quality staples amid macro uncertainty.

CL vs. XLP (Consumer Staples ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 1, 2026). Source: Yahoo Finance / Stock Price Data.

CL closed at $91.60 on July 30, 2026, up +7.3% from the Q1 earnings date close of $85.36. XLP gained +1.4% and SPY gained +3.2% over the same period, making CL a notable outperformer within staples. The stock dipped briefly to ~$84.87 on June 3 (Deutsche Bank conference day, where management flagged North America category deceleration), then recovered sharply, suggesting the market viewed the demand risk as manageable and already partially priced in. The stock reached a high of ~$95.13 on July 2 before pulling back modestly. At ~24x forward P/E on $3.80 FY2026 EPS consensus, the multiple is at a premium to the staples sector, leaving limited room for error but reflecting CL's Dividend King status and defensive quality. Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is management's June 3 disclosure of North America category deceleration beginning in early May — a new demand risk layered on top of the already-revised gross margin guidance — which is the primary uncertainty heading into the Q2 print.

• May 1, 2026 — Q1 2026 Earnings Beat; Gross Margin Guidance Revised Down. CL reported Q1 organic sales growth of 2.9% (vs. ~2.0% consensus) and operating EPS of $0.97 (vs. $0.946 consensus). Beat was broad-based across 4 of 5 divisions. Key negative: FY2026 gross profit margin guidance revised to down YoY (from previously expected up), citing ~$300M of incremental raw material and logistics costs. SGPP expanded with higher charge range ($450–$550M) and higher savings target ($200–$300M annualized). Implication: Sets a lower gross margin bar for Q2, but EPS guidance maintained signals P&L flexibility.
• May 1, 2026 — SGPP Expansion (8-K). Board approved expansion of the Strategic Growth and Productivity Program. Charges now estimated at $450–$550M (up from $400–$500M); annualized savings target raised to $200–$300M. Program end date unchanged at December 31, 2028. Implication: Incremental savings provide a funding source for growth investments and EPS support in 2027–2028.
• May 13, 2026 — Annual Meeting: Shareholders Back Board, Reject DEI and Independent Chairman Proposals (8-K). Routine governance outcome; no material business impact. Board composition and leadership structure unchanged.
• June 3, 2026 — Deutsche Bank Global Consumer Conference. CFO Stanley Sutula provided the most important post-Q1 update: (1) EPS guidance range maintained but "high end of the range has come down"; (2) North America categories "markedly slowed" beginning early May — only 3 weeks of data, but management is "preparing the business to respond"; (3) K-shaped economy dynamic intensifying, with strategy to serve both value (Cavity Protection) and premium (Optic White, hello) consumers; (4) Oral Care share losses in Q1 have "somewhat stabilized"; (5) Home Care brands (Fabuloso, Suavitel) cited as near-term North America growth levers. Implication: This is the most material incremental risk disclosure since Q1 earnings — the demand signal is the key unknown for Q2.
• March 17, 2026 — Segment Restructuring: New EMEA Unit Formed (8-K). Colgate restructured reporting segments, merging Africa/Eurasia into a new EMEA division. Recast historical financials filed. Implication: Improves transparency on European and African performance; no P&L impact.
• April 9, 2026 — Chief Legal Officer Succession Plan Announced (8-K). Routine leadership transition; no material business impact.
• Ongoing — Tariff Environment. North America bears the majority of CL's tariff costs. Management noted at Q1 earnings that the YoY tariff impact is expected to lessen as the year progresses (tariffs normalizing vs. minimal tariffs in prior year). Oil byproducts (resins, petrochemicals, fats, oils) up >20% YoY; logistics up ~10% YoY. Implication: Tariff headwind is a known, partially-absorbed risk; any de-escalation would be a positive catalyst for gross margin.
• Ongoing — Hill's Private Label Headwind Tapering. Private label impact was 260bps negative in Q1 2026. Management guided for ~20–30bps drag in Q2, largely resolved by H2 2026. Prescription Diet delivered double-digit growth in Q1. Implication: Hill's is a sequential tailwind story for H2 2026; Q2 should show meaningful improvement vs. Q1.

7. Peer Commentaries — Read-Through for CL Q2 2026

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for CL's Q2 setup — Unilever's Q2 2026 earnings (July 28) showed the strongest volume growth since 2010 and P&G's FY2026 Q4 results (July 29) confirmed Latin America strength and emerging market resilience — but North America category softness is a consistent theme across KMB, CHD, and PG, validating CL's own early-May demand warning. The read-through is mixed: global emerging market momentum is a tailwind for CL, while developed market (especially North America) category growth remains the swing factor.

Note: Only commentary about Q2 2026 / current quarter trends or forward-looking statements made after Q1 2026 earnings is included below. Prior-quarter result discussions are excluded.

Unilever (ULVR) — Q2 2026 Earnings (July 28, 2026) — STRONG POSITIVE READ-THROUGH

• Volume growth: Best since 2010. Unilever reported Q2 2026 underlying sales growth of 5.8%, driven by 5.5% volume growth — the best quarterly volume performance since 2010. H1 2026 underlying sales grew 4.8% with 4.2% volume. Read-through: Validates that global consumer staples demand is not collapsing; premium and volume-led growth is achievable in the current environment. Positive for CL's emerging market and global organic growth narrative.
• North America outperformance. Unilever's North America grew 2.7% in H1 with 3.2% volume, accelerating in Q2 to 2.6% growth and 4.4% volume, led by deodorants, skin cleansing, and prestige beauty. Read-through: Partially positive for CL — suggests North America consumer is not uniformly weak, but Unilever's categories (deodorants, beauty) differ from CL's oral care and home care focus. CL's North America softness may be more category-specific than macro-driven.
• Oral Care: Low single-digit growth, but softening. Unilever's oral care grew low single digits in H1 2026, but management expressed dissatisfaction, citing "significant increase in competition" in Asia (Pepsodent, Close Up). Plans to increase performance in H2. Read-through: Oral care category is competitive globally; CL's dominant market share and premium positioning (Optic White, Colgate Total) may insulate it, but the competitive intensity is a watch item.
• Emerging markets: Very strong. EM grew 8.3% in Q2 with 7.4% volume. India up 10% in Q2; Brazil returned to strong volume-led growth; Indonesia up 7%; Latin America up 7.9% with 8.8% volume. Read-through: Strong positive for CL's Latin America and Asia Pacific segments, which are key growth engines. Validates CL management's confidence in EM as an "all-weather" growth driver.
• Pricing building in H2. Unilever guided for H2 2026 growth of 4–5%, led by pricing as higher commodity costs are reflected. Inflationary pressures of $750–$900M for the year (up $350–$500M from start of year). Read-through: Commodity cost inflation is a sector-wide headwind, consistent with CL's gross margin revision. Pricing power in H2 is a potential tailwind for CL if it can execute mix management and RGM tools.

Procter & Gamble (PG) — FY2026 Q4 Earnings (July 29, 2026) — MIXED READ-THROUGH

• North America: Sell-in lagged sell-out. PG's North America organic sales were down 1% in Q4 FY2026, despite consumption (sell-out) growing 2%. A 3-point gap between sell-out and sell-in was attributed to retailer inventory reductions and Amazon Prime Day timing. Management expects North America momentum to "pick up during the semester" (July–December 2026) behind planned interventions. Read-through: Retailer inventory dynamics may be a headwind for CL's North America shipments in Q2 as well, but the underlying consumption picture (2% sell-out) is more constructive than shipment data suggests.
• Oral care: Down in Q4 FY2026. PG's oral care was down in Q4 FY2026, with management noting "still work to be done" in China on the paste side. However, PG sees significant long-term opportunity in "power oral care" (electric toothbrushes) in the US. Read-through: Oral care category softness at PG is a mild negative read-through for CL, though CL's oral care is more concentrated in manual toothbrushes and toothpaste in emerging markets where trends are better.
• Emerging markets: Solid. PG's enterprise markets grew 4% in Q4 FY2026, led by Latin America (+4% organic) and Europe enterprise (+5%). Greater China grew 4% with first share gains in 15 quarters. Read-through: Positive for CL's EM segments; Latin America category health confirmed by both PG and Unilever.
• FY2027 organic sales guidance: 1–3%. PG guided for FY2027 (July 2026–June 2027) organic sales growth of 1–3%, with base category growth assumption of ~2%. Management noted "softening in underlying market growth as inflation increased" in H2 FY2026. Read-through: Confirms that global category growth is decelerating, consistent with CL's 1–4% FY2026 organic guidance. The low end of PG's range (1%) is a cautionary signal for the sector.
• Consumer bifurcation confirmed. PG noted that "well-off" consumers continue normal behavior (larger pack sizes) while "more pressured" consumers look for smaller pack sizes and are highly promotion-sensitive. PG's portfolio is "more skewed to $100K+ income" consumers. Read-through: Validates CL's K-shaped economy strategy; CL's broader price-tier coverage (Cavity Protection at value, Optic/hello at premium) is well-positioned for this dynamic.

Kimberly-Clark (KMB) — Deutsche Bank Conference (June 4, 2026) — MIXED READ-THROUGH

• North America consumer: "Resilient, resilient." KMB CEO Michael Hsu described the North American consumer as resilient, noting that KMB's categories (diapers, bath tissue) are "pretty stable, daily use categories" where consumption doesn't change much with pricing. However, elevated fuel prices are impacting consumers at $100K income and below (90% of US households). Read-through: KMB's categories are more non-discretionary than CL's oral care; the resilience signal is partially applicable to CL's toothpaste/toothbrush business but less so to premium oral care and home care.
• Q2 2026 North America shipment headwinds. KMB flagged 70–80bps of Q2 North America shipment headwinds from the LA distribution center fire, plus lapping the strongest comp from Q2 2025 (North America volumes grew >5% in Q2 2025). Read-through: KMB-specific headwinds (fire, tough comp) are not directly applicable to CL, but the tough comp dynamic is a sector-wide consideration.
• Emerging markets: Very strong. KMB reported double-digit growth in Brazil, Indonesia up 30%, Vietnam up 40%, Korea diaper category up 20%+ due to a baby boom. Read-through: Strong positive for CL's EM segments; validates the structural growth opportunity in developing markets.
• No pricing increases planned; productivity-first approach. KMB CFO confirmed no update vs. Q1 on pricing/cost impacts, and committed to not cutting brand investments. Read-through: Consistent with CL's RGM-first, pricing-second approach; sector-wide discipline on promotions is a positive for category health.

Church & Dwight (CHD) — Q1 2026 Earnings (May 1, 2026) & Deutsche Bank Conference (June 2, 2026) — POSITIVE READ-THROUGH

• Category growth better than expected in Q1. CHD CEO noted Q1 category growth of ~3% (vs. initial expectation of ~2%), with March running at 3.5%. April came down slightly but CHD was "doing extremely well." Q2 2026 organic sales growth guided at ~3%. Read-through: Positive for CL — if CHD's categories (oral care via THERABREATH, home care, personal care) grew ~3% in Q1, it suggests the broader consumer staples category environment was healthier than feared entering Q2. However, CL's own early-May deceleration signal suggests a potential inflection post-Q1.
• Oral care: THERABREATH gaining share rapidly. THERABREATH achieved record share gains in Q1 (+3.5 points to 24.1% in mouthwash), solidifying #2 position. THERABREATH toothpaste launch "off to a great start." CHD's goal: grow oral care from $1B to $1.5B. Read-through: THERABREATH's rapid share gains in mouthwash are a competitive pressure on CL's Colgate mouthwash business. CL's oral care share losses in Q1 (noted at DB conference) may partly reflect THERABREATH's momentum.
• Consumer sentiment at all-time low; value tier growing. CHD noted consumer sentiment at "an all-time low" at the last reading, with consumers struggling with gas prices. Value tier of laundry continues to grow. Read-through: Validates CL's K-shaped economy strategy and the importance of serving both value and premium consumers. CL's Cavity Protection platform at the value tier is well-positioned.
• Strong volume growth in Q1 (~5%). CHD reported ~5% volume growth in Q1 2026, with ~half of growth from innovation. Distribution gains (7–11% TDP lift) are a "great tailwind" hitting now. Read-through: CHD's strong volume growth and distribution wins suggest the category environment was supportive in Q1; the question is whether this momentum carried into Q2 given the early-May deceleration signals.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by senior executives since Q1 earnings; the two open-market sales (EVP Controller and Chief People Officer) are small in size and likely routine. The COO Americas (Shane Grant) share withholding (code F) on June 16 is a tax-withholding event tied to equity vesting, not a discretionary sale — no negative signal. Director equity grants in May and July are routine annual compensation. Overall, insider activity is unremarkable and does not flag any concern.

Source: SEC Form 4 Filings (Insider Transaction Data). Open-market buys (Code P) and discretionary sells (Code S) only flagged above; Code A (grants/awards) and Code F (tax withholding) are non-discretionary and carry no directional signal. No open-market purchases by any insider since Q1 earnings. The absence of discretionary buying by senior management is neutral — not a negative signal given the stock's ~7% appreciation since Q1 earnings.

Appendix: Key Data Sources

• Visible Alpha Consensus and Actuals Data — All KPI actuals, consensus estimates, and revision history
• Stock Price Data (Yahoo Finance) — CL, XLP, SPY daily closing prices since May 1, 2026
• SEC Form 4 Filings (Insider Transaction Data) — CL insider transactions May 1 – July 30, 2026
• CL Q1 2026 Earnings Call Transcript (May 1, 2026) — Guidance, commentary, and forward-looking statements
• CL Deutsche Bank Global Consumer Conference Transcript (June 3, 2026) — Post-Q1 management commentary and North America demand update
• Peer Transcripts — Unilever Q2 2026 Earnings (Jul 28), PG FY2026 Q4 Earnings (Jul 29), KMB Deutsche Bank Conference (Jun 4), CHD Q1 2026 Earnings (May 1) and Deutsche Bank Conference (Jun 2)